Variable p53/Nrf2 crosstalk contributes to triptolide-induced hepatotoxic process.

[1]  Xiaoxv Dong,et al.  Ginsenoside Rb1 Attenuates Triptolide-Induced Cytotoxicity in HL-7702 Cells via the Activation of Keap1/Nrf2/ARE Pathway , 2022, Frontiers in Pharmacology.

[2]  J. York,et al.  Inhibition of p53 sulfoconjugation prevents oxidative hepatotoxicity and acute liver failure. , 2021, Gastroenterology.

[3]  M. Yan,et al.  Role of MicroRNA-155 in Triptolide-induced hepatotoxicity via the Nrf2-Dependent pathway. , 2021, Journal of ethnopharmacology.

[4]  Wenzhou Li,et al.  SIRT6 as a key event linking P53 and NRF2 counteracts APAP-induced hepatotoxicity through inhibiting oxidative stress and promoting hepatocyte proliferation , 2020, Acta pharmaceutica Sinica. B.

[5]  X. Pei,et al.  Olaquindox-Induced Liver Damage Involved the Crosstalk of Oxidative Stress and p53 In Vivo and In Vitro , 2020, Oxidative medicine and cellular longevity.

[6]  X. Pei,et al.  Molecular mechanism of olaquindox-induced hepatotoxicity and the hepatic protective role of curcumin. , 2020, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[7]  Dasheng Lu,et al.  Comprehensive analysis of transcriptomics and metabolomics to understand triptolide-induced liver injury in mice. , 2020, Toxicology letters.

[8]  A. Garufi,et al.  A ruthenium(II)-curcumin compound modulates NRF2 expression balancing the cancer cell death/survival outcome according to p53 status , 2020, Journal of experimental & clinical cancer research : CR.

[9]  M. Schwarz,et al.  Regulation of expression of drug-metabolizing enzymes by oncogenic signaling pathways in liver tumors: a review , 2019, Acta pharmaceutica Sinica. B.

[10]  Weixia Sun,et al.  P53/NRF2 mediates SIRT1's protective effect on diabetic nephropathy. , 2019, Biochimica et biophysica acta. Molecular cell research.

[11]  Ming Yan,et al.  Incidence and Etiology of Drug-Induced Liver Injury in Mainland China. , 2019, Gastroenterology.

[12]  H. Cai,et al.  Nrf2 participates in mechanisms for reducing the toxicity and enhancing the antitumour effect of Radix Tripterygium wilfordii to S180-bearing mice by herbal-processing technology , 2019, Pharmaceutical biology.

[13]  Meilin Liu,et al.  Preclinical Pharmacokinetics of Triptolide: A Potential Antitumor Drug. , 2019, Current drug metabolism.

[14]  Xiaoxv Dong,et al.  Triptolide Induces Apoptosis Through Fas Death and Mitochondrial Pathways in HepaRG Cell Line , 2018, Front. Pharmacol..

[15]  F. Shen,et al.  Triptolide induces p53‐dependent cardiotoxicity through mitochondrial membrane permeabilization in cardiomyocytes , 2018, Toxicology and applied pharmacology.

[16]  Xin He,et al.  Pharmacokinetic and Toxicological Characteristics of Tripterigium Glycosides and Their Derivatives. , 2018, Current drug metabolism.

[17]  H. Bi,et al.  p53 attenuates acetaminophen-induced hepatotoxicity by regulating drug-metabolizing enzymes and transporter expression , 2018, Cell Death & Disease.

[18]  Yongbo Peng,et al.  Mechanisms of Triptolide-Induced Hepatotoxicity and Protective Effect of Combined Use of Isoliquiritigenin: Possible Roles of Nrf2 and Hepatic Transporters , 2018, Front. Pharmacol..

[19]  Zhen-Ning Lu,et al.  DHPAC, a novel synthetic microtubule destabilizing agent, possess high anti-tumor activity in vincristine-resistant oral epidermoid carcinoma in vitro and in vivo. , 2017, The international journal of biochemistry & cell biology.

[20]  Jianming Xu,et al.  Rifampicin-induced injury in HepG2 cells is alleviated by TUDCA via increasing bile acid transporters expression and enhancing the Nrf2-mediated adaptive response. , 2017, Free Radical Biology & Medicine.

[21]  W. Gu,et al.  NRF2 Is a Major Target of ARF in p53-Independent Tumor Suppression. , 2017, Molecular cell.

[22]  M. Yan,et al.  The Ethanol Extract of Licorice (Glycyrrhiza uralensis) Protects against Triptolide-Induced Oxidative Stress through Activation of Nrf2 , 2017, Evidence-based complementary and alternative medicine : eCAM.

[23]  Xueping Zhou,et al.  Self-protection against triptolide-induced toxicity in human hepatic cells via Nrf2-ARE-NQO1 pathway , 2017, Chinese Journal of Integrative Medicine.

[24]  B. Water,et al.  Comprehensive Landscape of Nrf2 and p53 Pathway Activation Dynamics by Oxidative Stress and DNA Damage. , 2017, Chemical research in toxicology.

[25]  Jie Zhou,et al.  Toxicity of triptolide and the molecular mechanisms involved. , 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[26]  M. Huang,et al.  Activation of Nrf2 Protects against Triptolide-Induced Hepatotoxicity , 2014, PloS one.

[27]  Shu-yu Yang,et al.  Comparison of toxicokinetic and tissue distribution of triptolide-loaded solid lipid nanoparticles vs free triptolide in rats. , 2012, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[28]  M. Huang,et al.  Role of Nrf2 in protection against triptolide-induced toxicity in rat kidney cells. , 2012, Toxicology letters.

[29]  Z. Miao,et al.  Triptolide: structural modifications, structure-activity relationships, bioactivities, clinical development and mechanisms. , 2012, Natural product reports.

[30]  M. Kwak,et al.  Transcription factor Nrf2 maintains the basal expression of Mdm2: An implication of the regulation of p53 signaling by Nrf2. , 2011, Archives of biochemistry and biophysics.

[31]  Curtis D. Klaassen,et al.  Nrf2 the rescue: effects of the antioxidative/electrophilic response on the liver. , 2010, Toxicology and applied pharmacology.

[32]  Curtis D. Klaassen,et al.  Xenobiotic, Bile Acid, and Cholesterol Transporters: Function and Regulation , 2010, Pharmacological Reviews.

[33]  M. Toledano,et al.  The guardian recruits cops: the p53-p21 axis delegates prosurvival duties to the Keap1-Nrf2 stress pathway. , 2009, Molecular cell.

[34]  T. Russo,et al.  p53 Suppresses the Nrf2-dependent Transcription of Antioxidant Response Genes* , 2006, Journal of Biological Chemistry.

[35]  P. Chumakov,et al.  The antioxidant function of the p53 tumor suppressor , 2005, Nature Medicine.

[36]  Y. Shaul,et al.  A mechanism of ubiquitin-independent proteasomal degradation of the tumor suppressors p53 and p73. , 2005, Genes & development.

[37]  J. Lotem,et al.  Mdm-2 and ubiquitin-independent p53 proteasomal degradation regulated by NQO1 , 2002, Proceedings of the National Academy of Sciences of the United States of America.